Home
/
Cytek Biosciences, Inc.
/
Financials
/
Quarterly
Cytek Biosciences, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Cytek Biosciences, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Sep 30, 2024
$51.50M
Nov 7, 2024
Q2
2024
Jun 30, 2024
$46.62M
Aug 6, 2024
Q1
2024
Mar 31, 2024
$44.86M
May 8, 2024
Q3
2024
Sep 30, 2023
$48.00M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$49.69M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$37.09M
May 8, 2024
Q3
2023
Sep 30, 2022
$40.48M
Nov 14, 2023
Q2
2023
Jun 30, 2022
$40.16M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$35.06M
May 9, 2023
Q3
2022
Sep 30, 2021
$34.38M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$30.41M
Aug 10, 2022
Q1
2022
Mar 31, 2021
$24.27M
May 12, 2022
Q3
2021
Sep 30, 2020
$25.10M
Nov 12, 2021
Q2
2021
Jun 30, 2020
$19.14M
Sep 3, 2021
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$52.29M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$45.60M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$41.46M
May 8, 2025
Q3
2025
Sep 30, 2024
$51.50M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$46.62M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$44.86M
May 8, 2025
Q3
2024
Sep 30, 2023
$48.00M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$49.69M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$37.09M
May 8, 2024
Q3
2023
Sep 30, 2022
$40.48M
Nov 14, 2023
Q2
2023
Jun 30, 2022
$40.16M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$35.06M
May 9, 2023
Q3
2022
Sep 30, 2021
$34.38M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$30.41M
Aug 10, 2022
Q1
2022
Mar 31, 2021
$24.27M
May 12, 2022
Q3
2021
Sep 30, 2020
$25.10M
Nov 12, 2021
Q2
2021
Jun 30, 2020
$19.14M
Sep 3, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2025
Mar 31, 2025
($11.40M)
May 8, 2025
Q1
2025
Mar 31, 2024
($6.17M)
May 8, 2025
Q2
2023
Jun 30, 2023
($4.39M)
Aug 8, 2023
Q1
2023
Mar 31, 2023
($6.81M)
May 9, 2023
Q3
2022
Sep 30, 2022
$1.63M
Nov 9, 2022
Q2
2023
Jun 30, 2022
($702.0K)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($2.16M)
May 9, 2023
Q3
2022
Sep 30, 2021
$1.42M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$2.67M
Aug 10, 2022
Q3
2021
Jun 30, 2021
$2.67M
Nov 12, 2021
Q1
2022
Mar 31, 2021
$102.0K
May 12, 2022
Q3
2021
Mar 31, 2021
$102.0K
Nov 12, 2021
Q2
2022
Mar 31, 2021
$102.0K
Aug 10, 2022
Q3
2021
Sep 30, 2020
$6.54M
Nov 12, 2021
Q3
2021
Jun 30, 2020
$8.11M
Nov 12, 2021
Q2
2021
Jun 30, 2020
$8.11M
Sep 3, 2021
Q3
2021
Mar 31, 2020
($839.0K)
Nov 12, 2021
Q2
2021
Mar 31, 2020
($839.0K)
Sep 3, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($9.19M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($10.62M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($14.98M)
May 8, 2025
Q3
2025
Sep 30, 2024
($4.25M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($8.53M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($10.73M)
May 8, 2025
Q3
2024
Sep 30, 2023
($6.42M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($9.13M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($12.16M)
May 8, 2024
Q3
2023
Sep 30, 2022
$1.36M
Nov 14, 2023
Q2
2023
Jun 30, 2022
($891.0K)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($2.36M)
May 9, 2023
Q3
2022
Sep 30, 2021
$2.90M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$3.81M
Aug 10, 2022
Q1
2022
Mar 31, 2021
$1.13M
May 12, 2022
Q3
2021
Sep 30, 2020
$6.71M
Nov 12, 2021
Q2
2021
Jun 30, 2020
($218.0K)
Sep 3, 2021